NCT05962216View on ClinicalTrials.gov

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
PsychosisDepression
Interventions
DRUG

Brexpiprazole

Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders

Trial Locations (1)

000000

RECRUITING

Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Dr. Albert Kar-Kin Chung

OTHER

NCT05962216 - Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders | Biotech Hunter | Biotech Hunter